Bridging Guidelines and Real-World Practice in IgA Nephropathy

Explore the complexities of IgA nephropathy, its treatment advancements, and the challenges in early diagnosis and management in nephrology.

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes.

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes.

Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of Nefecon in patient care.

Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of Nefecon in patient care.

Explore KDIGO 2025 IgA nephropathy shifts: treat earlier at proteinuria >0.5 g/day, dual-pathway therapy aims to preserve GFR.

New KDIGO updates push earlier IgA nephropathy treatment, targeting immune pathways and nephron protection to cut proteinuria and slow eGFR decline.

Learn why Oxford scores predict IgA nephropathy outcomes, and how supportive drugs plus low-salt lifestyle protect remaining nephrons.

Learn how targeted-release budesonide treats IgA nephropathy, cutting proteinuria and slowing GFR decline with fewer steroid side effects.

Explore emerging IgA nephropathy therapies—complement and BAFF/APRIL inhibitors, targeted budesonide—and why long‑term safety data still lags.

In this episode, Overcoming Access Barriers and Step-Edit Challenges in IgA Nephropathy Care, the panelists explore the following questions: What barriers exist to real-world use, particularly around payer policies or access? Many plans require a systemic steroid step-edit; why might this be inappropriate for IgAN?

In Advocacy Strategies and the Expanding Role of Novel Therapies in IgA Nephropathy, our panel delves into the following critical questions: What strategies can clinicians use to advocate for access or navigate step edits? How might real-world data and ongoing registries (like RaDaR) support broader adoption and payer confidence?

This episode, titled Rethinking KDIGO Guidance and Payer Models in the Era of Targeted IgA Nephropathy Therapies, features expert nephrologists discussing the following critical questions: What updates to KDIGO will likely need to be made in view of these novel therapies being approved? How should payers and health systems think differently about treating this disease?

In the final episode, Near-Term Priorities for Transforming Clinical Practice in IgA Nephropathy, the panelist explored the following critical question: What do you hope to see in the next 1–2 years in terms of clinical practice change?